Director/PDMR Shareholding
EDX Medical Group plc announced that Professor Sir Christopher Evans, founder and Chief Scientific Officer, purchased 45,500 ordinary shares at 10.75 pence per share on January 2, 2026. This follows a previous purchase of 57,304 shares announced on January 2, 2026. Professor Evans now holds 136,119,743 shares, representing 35.21% of the issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your EDX notes
CAMBRIDGE, UK: EDX Medical Group, plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that Professor Sir Christopher Evans, founder and Chief Scientific Officer of the Company, purchased 45,500 ordinary shares in the Company on January 2, 2026, at a price per share of 10.75 pence.
This transaction follows the recent purchase of 57,304 ordinary shares in the Company by Professor Evans, as was previously announced on 2 January 2026.
Professor Evans now owns 136,119,743 shares in the Company, representing 35.21% of the issued share capital.
The directors of the Company accept responsibility for the contents of this announcement.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Professor Sir Christopher Evans |
| 2 | Reason for the notification | |
| a) | Position/status | Board Director / Chief Scientific Officer |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | EDX Medical Group PLC |
| b) | LEI | 213800BZVJZTMCZ6DJ63 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each |
| Identification code | ISIN: GB00BNDMJS47 | |
| b) | Nature of the transaction | Purchase of shares on market |
| c) | Price(s) and volume(s) | |
| Price | Volume | |
| £0.1075 | 45,500 | |
| d) | Aggregated information | |
| - Aggregated volume | 45,500 | |
| - Price | £0.1075 | |
| e) | Date of the transaction | 2026-01-02 |
| f) | Place of the transaction | AQSG - Aquis Growth Market (Equity) |
- Commission Delegated Regulation (EU) 2016/522 of 17 December 2015 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council as regards an exemption for certain third countries public bodies and central banks, the indicators of market manipulation, the disclosure thresholds, the competent authority for notifications of delays, the permission for trading during closed periods and types of notifiable managers' transactions (see page 1 of this Official Journal).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.